In the world of Big Pharma, growth is a precious commodity these days. Allergan (NYSE: AGN )
is a noteworthy exception, though, as the company continues to see
strong demand for cornerstone products like Botox an Restasis, as well
as its facial aesthetics line. Allergan's pipeline is somewhat more
limited than an investor might normally prefer, but the company has been
active in pursuing follow-on indications for existing drugs and has had
a higher than normal "hit" rate for its pipeline. Though there are
frustratingly few true bargains in the pharma space today, Allergan
continues to look at least as though it will remain a solid holding.
Continue here:
Can Allergan's Growth Continue?
No comments:
Post a Comment